Join
Live feed
·
PRReleasevia Quantisnow
Intra-Cellular Therapies Inc. logo

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

ByQuantisnow·Wall Street's wire, on your screen.
ITCI· Intra-Cellular Therapies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ITCI (Intra-Cellular Therapies Inc.) and more on Quantisnow.